Annexon (NASDAQ:ANNX - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.
Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Annexon Price Performance
Shares of NASDAQ ANNX traded down $0.10 during mid-day trading on Friday, reaching $1.61. 1,210,735 shares of the company's stock traded hands, compared to its average volume of 1,789,278. The business has a 50-day simple moving average of $2.00 and a 200 day simple moving average of $3.87. The stock has a market cap of $176.09 million, a P/E ratio of -1.53 and a beta of 1.24. Annexon has a 1-year low of $1.29 and a 1-year high of $7.85.
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Annexon in a research note on Tuesday, March 4th.
Check Out Our Latest Research Report on ANNX
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Recommended Stories
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
